Approval may validate the science, but it does not secure commercial success. That outcome is determined by the decisions made before launch.
Eli Lilly's imlunestrant (Inluriyo) for breast cancer has received a new FDA approval, in combination with CDK4/6 inhibitor abemaciclib (Verzenio).
Leela Barham looks at the discussion on non-submissions to the HTA body NICE, informed by the latest metrics for VPAG.
Novo has moved a step closer to EU approval of its long-acting haemophilia A therapy, Frehemgo, which could be a future blockbuster.
The chairs of six UK parliamentary committees have asked the National Audit Office to investigate the UK-US pharma deal and its impact on the NHS.
Editor's Picks
